Skip to Content

Akzo Nobel NV

AKZA: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€27.00HvwtwPrnvfhb

Solid Execution for AkzoNobel in Fourth Quarter; Shares Undervalued

Narrow-moat AkzoNobel reported fourth-quarter EBIT of EUR 209 million, down 29% over 2020 but broadly in line with Vara consensus. Raw material Inflation (less than 30% in the quarter) and supply chain issues continue to be a major drag but AkzoNobel is executing well with continued price increases, including 12.5% in the fourth quarter and 14% in December. We don’t expect to make a material change to our EUR 107 fair value estimate. At current levels, the shares look undervalued.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of AKZA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center